
Kadmon Holdings, Inc. Revenue | KDMN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Kadmon Holdings, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 8.29 M | 5.1 M | 1.4 M | 12.3 M | 26.1 M | 35.7 M | 95 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95 M | 1.4 M | 26.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
678 M | $ 76.31 | 0.69 % | $ 5.66 B | ||
|
Karyopharm Therapeutics
KPTI
|
146 M | $ 0.67 | 1.51 % | $ 7.33 K | ||
|
Keros Therapeutics
KROS
|
244 M | $ 11.52 | 1.41 % | $ 429 M | ||
|
Krystal Biotech
KRYS
|
389 M | $ 334.85 | 3.9 % | $ 9.69 B | ||
|
Kura Oncology
KURA
|
67.5 M | $ 10.62 | 0.09 % | $ 931 M | ||
|
Kymera Therapeutics
KYMR
|
39.2 M | $ 109.85 | 2.29 % | $ 9.28 B | ||
|
Kazia Therapeutics Limited
KZIA
|
42 K | $ 9.35 | 0.86 % | $ 143 M | ||
|
Lineage Cell Therapeutics
LCTX
|
14.6 M | $ 0.93 | 2.73 % | $ 214 M | ||
|
Legend Biotech Corporation
LEGN
|
627 M | $ 18.77 | 1.1 % | $ 6.92 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
268 M | $ 306.77 | 1.26 % | $ 5.93 B | ||
|
Longeveron
LGVN
|
1.2 M | $ 2.51 | 0.39 % | $ 44.1 B | ||
|
Eli Lilly and Company
LLY
|
65.2 B | $ 1 143.12 | 0.02 % | $ 1.03 T | ||
|
Lipocine
LPCN
|
1.98 M | $ 2.07 | 0.98 % | $ 11.3 M | ||
|
Liquidia Corporation
LQDA
|
158 M | $ 27.64 | 2.32 % | $ 2.38 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
49.8 M | $ 1.74 | 0.82 % | $ 632 M | ||
|
Seres Therapeutics
MCRB
|
789 K | $ 2.85 | 0.34 % | $ 25.2 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
958 M | $ 493.62 | 0.1 % | $ 11.1 B | ||
|
MediWound Ltd.
MDWD
|
21.8 M | $ 13.51 | 0.22 % | $ 368 M | ||
|
Mesoblast Limited
MESO
|
17.2 M | $ 14.22 | 0.99 % | $ 17.2 B | ||
|
MacroGenics
MGNX
|
150 M | $ 3.77 | 5.31 % | $ 238 M | ||
|
MeiraGTx Holdings plc
MGTX
|
81.4 M | $ 10.92 | 1.2 % | $ 878 M | ||
|
Mirum Pharmaceuticals
MIRM
|
521 M | $ 81.43 | 0.07 % | $ 4.09 B | ||
|
MannKind Corporation
MNKD
|
349 M | $ 3.82 | 0.53 % | $ 1.17 B | ||
|
MediciNova
MNOV
|
410 K | $ 1.76 | 0.28 % | $ 86.4 M | ||
|
Mereo BioPharma Group plc
MREO
|
36.5 M | $ 0.39 | 2.16 % | $ 311 M | ||
|
Merck & Co.
MRK
|
65 B | $ 139.54 | 0.34 % | $ 349 B | ||
|
Marker Therapeutics
MRKR
|
3.55 M | $ 1.06 | 0.95 % | $ 16.2 M | ||
|
Moderna
MRNA
|
1.94 B | $ 203.21 | 6.95 % | $ 79 B | ||
|
Maravai LifeSciences Holdings
MRVI
|
186 M | $ 8.52 | 7.85 % | $ 1.23 B | ||
|
Matinas BioPharma Holdings
MTNB
|
1.1 M | $ 2.82 | 6.82 % | $ 15.4 M | ||
|
RAPT Therapeutics
RAPT
|
1.53 M | - | - | $ 2.36 B | ||
|
Neurocrine Biosciences
NBIX
|
2.86 B | $ 144.21 | 0.72 % | $ 14.3 B | ||
|
Nanobiotix S.A.
NBTX
|
32.6 M | $ 25.1 | 0.16 % | $ 1.2 T | ||
|
Minerva Neurosciences
NERV
|
41.2 M | $ 3.32 | 1.22 % | $ 28.1 M | ||
|
Nektar Therapeutics
NKTR
|
55.2 M | $ 42.22 | 2.2 % | $ 712 M | ||
|
Nkarta
NKTX
|
115 K | $ 2.53 | 0.59 % | $ 187 M | ||
|
Nurix Therapeutics
NRIX
|
84 M | $ 22.88 | 0.09 % | $ 1.98 B | ||
|
Nuvation Bio
NUVB
|
62.9 M | $ 4.95 | 1.07 % | $ 1.69 B | ||
|
Novavax
NVAX
|
1.12 B | $ 12.56 | 20.08 % | $ 2.03 B | ||
|
Novo Nordisk A/S
NVO
|
309 B | $ 37.54 | 0.59 % | $ 167 B | ||
|
Novartis AG
NVS
|
49.9 B | $ 140.93 | 0.01 % | $ 273 B |